BOSTON, Aug. 4, 2022
/PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading horizontal
platform for cell programming, today announced that Kathy Hopinkah Hannan, PhD, CPA has joined its
Board of Directors, effective August 2,
2022. Dr. Hannan brings over thirty years of experience as a
senior C-Suite executive, corporate advisor, independent board
director and strategist leading significant operations and high
priority initiatives.
"As a pioneer in synthetic biology, Ginkgo Bioworks is
undertaking critical work to make biology easier to engineer and to
enable a more sustainable future," said Dr. Hannan. "I am honored
to join Ginkgo's Board at such a significant time in the company's
history, and look forward to working with Ginkgo's incredible team
as they use synthetic biology to unlock innovations across
industries."
Dr. Hannan is a retired senior partner from KPMG LLP, where she
also served as Vice Chair. She brings extensive governance
experience through her corporate board roles with Annaly Capital
Management, Otis Worldwide Corporation, and Carpenter Technology
Corporation, as well as her roles as Chair of the Board of Trustees
for the Smithsonian National Museum of the American Indian and
formerly as Chair of the Board of Directors of Girl Scouts of the
USA. A member of the Ho-Chunk
Nation, Dr. Hannan served as a commissioner for the Tribal
Employment Rights Office and was a presidential appointee to the
National Advisory Council on Indian Education. She also served as a
member of the Committee to establish the Board of Directors for the
Ho-Chunk Tribe's corporation under Section 17 of the Indian
Reorganization Act.
"Dr. Hannan brings invaluable experience as a leader in
enterprise sustainability and organizational effectiveness, with an
impressive track record for leading key financial and advisory
services for clients," said Marijn Dekkers, Chair of the Board of
Directors for Ginkgo Bioworks. "Dr. Hannan's industry knowledge and
financial acumen is a welcome addition to our Board as Ginkgo
continues to grow as a public company. We are looking forward to
working with her."
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program
cells as easily as we can program computers. The company's platform
is enabling biotechnology applications across diverse markets, from
food and agriculture to industrial chemicals to pharmaceuticals.
Ginkgo has also actively supported a number of COVID-19 response
efforts, including K-12 pooled testing, vaccine manufacturing
optimization and therapeutics discovery. For more information,
visit www.ginkgobioworks.com.
Forward-Looking Statements of
Ginkgo Bioworks
This press release contains certain forward-looking statements
within the meaning of the federal securities laws, including
statements regarding Ginkgo's growth and potential innovations.
These forward-looking statements generally are identified by the
words "believe," "can," "project," "potential," "expect,"
"anticipate," "estimate," "intend," "strategy," "future,"
"opportunity," "plan," "may," "should," "will," "would," "will be,"
"will continue," "will likely result," and similar expressions.
Forward-looking statements are predictions, projections and other
statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to: (i) the effect of Ginkgo's
business combination with Soaring Eagle Acquisition Corp. ("Soaring
Eagle") on Ginkgo's business relationships, performance, and
business generally, (ii) risks that the business combination
disrupts current plans of Ginkgo and potential difficulties in
Ginkgo's employee retention, (iii) the outcome of any legal
proceedings that may be instituted against Ginkgo related to its
business combination with Soaring Eagle, (iv) volatility in the
price of Ginkgo's securities now that it is a public company due to
a variety of factors, including changes in the competitive and
highly regulated industries in which Ginkgo operates and plans to
operate, variations in performance across competitors, changes in
laws and regulations affecting Ginkgo's business and changes in the
combined capital structure, (v) the ability to implement business
plans, forecasts, and other expectations after the completion of
the business combination, and identify and realize additional
opportunities, (vi) the risk of downturns in demand for products
using synthetic biology, (vii) the unpredictability of the duration
of the COVID-19 pandemic and the demand for COVID-19 testing and
the commercial viability of our COVID-19 testing business, and
(viii) changes to the biosecurity industry, including due to
advancements in technology, emerging competition and evolution in
industry demands, standards and regulations. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the "Risk Factors" section of Ginkgo's quarterly report on Form
10-Q filed with the U.S. Securities and Exchange Commission (the
"SEC") on May 16, 2022 and other
documents filed by Ginkgo from time to time with the SEC. These
filings identify and address other important risks and
uncertainties that could cause actual events and results to differ
materially from those contained in the forward-looking statements.
Forward-looking statements speak only as of the date they are made.
Readers are cautioned not to put undue reliance on forward-looking
statements, and Ginkgo assumes no obligation and does not intend to
update or revise these forward-looking statements, whether as a
result of new information, future events, or otherwise. Ginkgo does
not give any assurance that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-appoints-kathy-hopinkah-hannan-to-its-board-of-directors-301599762.html
SOURCE Ginkgo Bioworks